Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

Share Price is delayed by 15 minutes
Get Live Data
8.65    0.00 (0.00%)
Bid:
8.30
Ask:
9.00
Spread: 0.70 (8.434%)
Market Cap: £18.86m
IXI Live PriceLast checked at - London Stock Exchange

Intraday Ixico Share Chart

Appointment of Non-Exec

5 Jun 2006 07:00

Phytopharm PLC05 June 2006 Company Contact: U.K. Investor Relations Contact:Phytopharm plc Financial DynamicsDr Richard Dixey David Yates / Ben Atwell +44 207 831 3113+44 7867 782000Dr Daryl Rees+44 1480 437 697www.phytopharm.com Appointment of Non Executive Director GODMANCHESTER, Cambridgeshire, U.K. (June 5 2006) - Phytopharm plc (LSE: PYM;NASDAQBB: PHYOF; PHYOY) ("Phytopharm") announces the appointment with immediateeffect of Mr A D (Sandy) Morrison, former CEO of Lipton Ltd (a Unileversubsidiary) as a Non-executive Board Director of Phytopharm. Mr Morrison (aged 59) has a BSc (Hons) in applied chemistry (Strathclyde) andhas over 20 years experience in general and international management, globalsupply chain and R&D. He was Chief Executive Officer of Lipton Ltd, the globaltea sourcing organization for Unilever with operations in six countries for fiveyears from 2000 to 2006. During Mr Morrison's period as CEO, substantialoperational & financial improvements were made to the Unilever global tea supplychain and he also played a significant part in addressing issues in theinternational tea trade. In the immediate years prior to 2000, Mr Morrison hadsenior international food & beverage roles for Unilever outside the UK, in thesupply chain and in R&D, both at the Rotterdam head office and in the Unileverfood and beverage subsidiary in Australia. Commenting on the appointment, Mr Gordon Stevens, Chairman of Phytopharm, said;"the appointment of a person of this calibre and experience to the Board ofPhytopharm will provide an important asset to the Company and I am delightedthat Sandy will be joining us. This appointment begins a process ofrestructuring of the Board and I look forward to the announcement of furtherappointments in due course." There are no further details required to be disclosed under paragraph 9.6.13R ofthe Listing Rules or Disclosure Rule 3.1.2R. -ENDS- NOTES TO EDITORS Phytopharm plc Phytopharm is a pharmaceutical company with a plant extract division. Thepharmaceutical division is dedicated to the discovery and development of singlechemicals as prescription medicines and the plant extract division is focussedon the development of plant extracts as functional foods and veterinaryproducts.. More information concerning Phytopharm's activities can be found on its web site at http://www.phytopharm.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
8th Jun 20267:00 amRNSScientific advisors & partners update
22nd May 20267:00 amRNS-RCompany presentation at Mello 2026
21st May 20267:00 amRNSContract win and contract extension
19th May 20267:00 amRNSInterim results for six months ending 31/03/2026
12th May 20267:00 amRNSIXICO Updates AI Neuroimaging Platform
28th Apr 20262:31 pmRNSHolding(s) in Company
28th Apr 20261:50 pmRNSHolding(s) in Company
28th Apr 202611:45 amRNSHolding(s) in Company
28th Apr 202610:49 amRNSHolding(s) in Company
27th Apr 20264:02 pmRNSHolding(s) in Company
27th Apr 20263:57 pmRNSHolding(s) in Company
27th Apr 20263:55 pmRNSHolding(s) in Company
27th Apr 20261:51 pmRNSHolding(s) in Company
27th Apr 202611:13 amRNSHolding(s) in Company
24th Apr 20263:30 pmRNSHolding(s) in Company
22nd Apr 202612:40 pmRNSIssue of Equity
21st Apr 20267:00 amRNSTrading Update
16th Apr 202612:01 pmRNSResult of GM and Update on Issue of Equity
7th Apr 20261:14 pmRNSResult of Retail Offer
31st Mar 20267:01 amRNSRetail Offer
31st Mar 20267:00 amRNSPlacings and Subscription
26th Mar 20267:00 amRNSCollaboration with Medidata
26th Feb 20267:00 amRNSValidation of Neuroimaging Technology Platform
12th Feb 20268:48 amRNSCorrection: c.£1.5 million Contract Extension
12th Feb 20267:00 amRNSc.£1.5 million Contract Extension
5th Feb 20267:00 amRNSAppointment of Chief Commercial Officer
23rd Jan 20265:05 pmRNSResults of AGM
9th Dec 20257:05 amRNSShare option award
9th Dec 20257:00 amRNSFinancial Results for year ended 30 September 2025
1st Dec 20257:00 amRNSOperational Update
27th Nov 20257:00 amRNSNotice of 2025 Full Year Results and IMC
17th Nov 20257:00 amRNSClinical Trial Contract Win
3rd Nov 20252:30 pmRNSCapital Markets Day Presentation and Video
16th Oct 20257:00 amRNSTrading Update
15th Oct 20257:00 amRNSNew contract win and contract extension
30th Sep 20257:00 amRNSNotice of Capital Markets Day
12th Aug 20257:00 amRNSContract Win
22nd Jul 20257:00 amRNSStrategic Data Partnership with GAP
17th Jul 20257:00 amRNSTrading Update
13th Jun 20258:03 amRNSShare option awards and PDMR Dealing
10th Jun 20257:00 amRNSFDA Clearance of Alzheimer's Diagnostic Biomarker
20th May 20256:00 pmRNSHolding(s) in Company
20th May 20257:00 amRNSHalf-year Report
8th May 202511:30 amRNSHolding(s) in Company
6th May 20257:00 amRNSNotice of Interim Results & Investor Presentation
16th Apr 20257:00 amRNSTrading Update
27th Feb 20257:00 amRNSContract Win
12th Feb 20257:00 amRNSFurther Validation of IXICO’s AI Imaging Platform
7th Feb 20253:00 pmRNSIssue of share options and PDMR dealing
24th Jan 20252:16 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.